BioMark Diagnostics Inc. products

BioMark’s initial liquid biopsy assay detects SSAT1 using an FDA approved drug. SSAT1 is an enzyme with elevated levels in numerous cancers. The assay targets a well researched and understood metabolic pathway. BioMark of a few unique companies using safe therapeutic agents for diagnostic indication. As a non-invasive cost effective red alert tool, it is valuable to physicians around the world. It is a valuable tool for early stage cancer detection.

BioMark has invested in and developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early stage diagnosis of lung cancer.